barzolvolimab — Topline data
late 2026
Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling; Phase 2 topline data in AD expected in late 2026Source filing
CLDX biotech catalysts & pipeline
CELLDEX THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
barzolvolimab — NDA/BLA submission
2027
Treatment will continue in both trials to 52 weeks; BLA submission anticipated in 2027Source filing